Keros Therapeutics, Inc. KROS
Keros Therapeutics, Inc. (Nasdaq: KROS) is a rare genetic drug developer. Its lead program, rinvatercept (KER-065), is in Phase 2 for Duchenne muscular dystrophy (DMD). Its next catalyst on record is rinvatercept (KER-065): regulatory engagement on Phase 2 trial design in ALS (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: rinvatercept (KER-065) — regulatory engagement on Phase 2 trial design in ALS (H2 2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| elritercept (KER-050) | myelodysplastic syndromes (MDS) - lower-risk | protein/peptide | Phase 3 |
| elritercept (KER-050) | myelofibrosis | protein/peptide | Phase 3 |
| rinvatercept (KER-065) | Duchenne muscular dystrophy (DMD) | protein/peptide | Phase 2 |
| rinvatercept (KER-065) | amyotrophic lateral sclerosis (ALS) | protein/peptide | Pre-clinical |
Recent results and decisions
- Sep 29, 2026started Takeda dosed first patient in ELRiSE MF, a Phase 3 trial of elritercept in myelofibrosis patients with anemia on ruxolitinib, triggering a $20 million milestone payment to Keros.
The milestone marks another important step forward for the elritercept program.
Filing - started First patient dosed in Phase 2 clinical trial of rinvatercept in patients with Duchenne muscular dystrophy in September 2026.
In September 2026, Keros announced the first patient was dosed in the Phase 2 clinical trial of rinvatercept in patients with DMD.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 rare genetic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.